NASDAQ:ECOR electroCore - ECOR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding electroCore, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.37 +0.02 (+5.71%) (As of 02/2/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.35▼$0.3850-Day Range$0.26▼$0.4052-Week Range$0.20▼$0.70Volume82,586 shsAverage Volume241,526 shsMarket Capitalization$26.33 millionP/E RatioN/ADividend YieldN/APrice Target$1.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media electroCore MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside44,697.3% Upside$165.75 Price TargetShort InterestHealthy1.13% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$186,650 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.30) to ($0.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.34 out of 5 starsMedical Sector246th out of 1,030 stocksElectromedical Equipment Industry6th out of 24 stocks 3.5 Analyst's Opinion Consensus RatingelectroCore has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $165.75, electroCore has a forecasted upside of 44,697.3% from its current price of $0.37.Amount of Analyst CoverageelectroCore has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.13% of the outstanding shares of electroCore have been sold short.Short Interest Ratio / Days to CoverelectroCore has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in electroCore has recently increased by 4.23%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldelectroCore does not currently pay a dividend.Dividend GrowthelectroCore does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ECOR. Previous Next 2.5 News and Social Media Coverage News SentimentelectroCore has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.Search Interest20 people have searched for ECOR on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows6 people have added electroCore to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, electroCore insiders have bought more of their company's stock than they have sold. Specifically, they have bought $186,650.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.11% of the stock of electroCore is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.76% of the stock of electroCore is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for electroCore are expected to grow in the coming year, from ($0.30) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of electroCore is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of electroCore is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioelectroCore has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About electroCore (NASDAQ:ECOR) StockelectroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The company was founded by Joseph P. Errico, Steven M. Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Rockaway, NJ.Read More Receive ECOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for electroCore and its competitors with MarketBeat's FREE daily newsletter. Email Address ECOR Stock News HeadlinesJanuary 17, 2023 | finance.yahoo.comelectroCore Announces Expected Record 4Q 2022 Revenue of $2.5M; Provides Business UpdateDecember 20, 2022 | finance.yahoo.comelectroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, Truvaga™February 2, 2023 | Investing Trends (Ad)The Biggest "Missing Ingredient" in the $7 Trillion EV MarketChina has owned the graphite market for decades. But the U.S. just added graphite to a list of super-critical minerals... "essential for America's National Defense." Perfect timing for a "made in America" graphite company looking to mine, manufacture, and recycle graphite for the booming electric car market.December 7, 2022 | finance.yahoo.comelectroCore Announces Issuance of Two New U.S. PatentsNovember 18, 2022 | finance.yahoo.comgammaCore Sapphire™ Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical AssociationNovember 14, 2022 | finance.yahoo.comelectroCore to Participate at Canaccord Genuity MedTech and Diagnostics and Digital Health & Services ForumNovember 6, 2022 | seekingalpha.comelectroCore, Inc. (ECOR) Q3 2022 Earnings Call TranscriptNovember 6, 2022 | markets.businessinsider.comMaxim Group Keeps Their Buy Rating on Electrocore (ECOR)February 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.November 4, 2022 | finance.yahoo.comECOR: Currency Pressures Nick OUS RevenuesNovember 3, 2022 | finance.yahoo.comelectroCore Announces Third Quarter 2022 Financial ResultsNovember 1, 2022 | finance.yahoo.comelectroCore and Joerns Healthcare Partner to Expand Use Of gammaCore™ Vagus Nerve Technology for Headache SufferersNovember 1, 2022 | finance.yahoo.comelectroCore, Inc. Announces Distribution Agreement with Joerns Healthcare, LLCOctober 27, 2022 | finance.yahoo.comelectroCore to Announce Third Quarter 2022 Financial Results on November 3October 20, 2022 | finance.yahoo.comgammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain InjuryOctober 17, 2022 | globenewswire.comGlobal Cluster Headache Market Size to grow USD 626 Billion by 2030 | CAGR of 6.5%; Spherical Insights & Consulting - GlobeNewswireOctober 17, 2022 | uk.investing.comBank of America, Charles Schwab And 3 Stocks To Watch Heading Into Monday By Benzinga - Investing.com UKOctober 14, 2022 | globenewswire.comelectroCore Provides Select Third Quarter 2022 Financial Guidance - GlobeNewswireOctober 14, 2022 | finance.yahoo.comelectroCore Provides Select Third Quarter 2022 Financial GuidanceOctober 10, 2022 | globenewswire.comGlobal Neuromodulation Market to Reach $8.9 Billion by 2027 - GlobeNewswireSeptember 21, 2022 | globenewswire.comelectroCore Strengthens Patent Portfolio with Issuance of Four New US Patents - GlobeNewswireSeptember 21, 2022 | finance.yahoo.comelectroCore Strengthens Patent Portfolio with Issuance of Four New U.S. PatentsSeptember 20, 2022 | benzinga.comStellantis Invests in Italian Industrial Footprint Transformation to Develop Sustainable Activity - BenzingaSeptember 20, 2022 | benzinga.comThe International Hospitality Institute Names Paul Miller, Questex's CEO, One of the 100 Most Powerful Pe - BenzingaSeptember 20, 2022 | benzinga.comAnduin Appoints Drake Paulson as VP of Strategic Partnerships - BenzingaSeptember 20, 2022 | benzinga.comNew AARP Member Benefits Announced for Fall 2022 - BenzingaSeptember 20, 2022 | globenewswire.comElectrocore Announces Date for Fiscal Year 2022 Annual Meeting and Deadlines for Stockholder Proposals - GlobeNewswireSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ECOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for electroCore and its competitors with MarketBeat's FREE daily newsletter. Email Address ECOR Company Calendar Last Earnings11/04/2021Today2/02/2023Next Earnings (Estimated)3/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ECOR CUSIPN/A CIK1560258 Webwww.electrocore.com Phone(973) 290-0097FaxN/AEmployees52Year FoundedN/APrice Target and Rating Average Stock Price Forecast$165.75 High Stock Price Forecast$330.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+305.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,220,000.00 Net Margins-283.41% Pretax Margin-288.99% Return on Equity-72.36% Return on Assets-59.64% Debt Debt-to-Equity RatioN/A Current Ratio3.81 Quick Ratio3.51 Sales & Book Value Annual Sales$5.45 million Price / Sales4.83 Cash FlowN/A Price / Cash FlowN/A Book Value$0.52 per share Price / Book0.71Miscellaneous Outstanding Shares71,170,000Free Float61,842,000Market Cap$26.33 million OptionableNot Optionable Beta1.04 Key ExecutivesDaniel S. GoldbergerChief Executive Officer & DirectorMichael RomaniwExecutive Vice President-Systems & OperationsBrian M. PosnerSecretary, Chief Financial & Accounting OfficerPeter S. StaatsChief Medical OfficerBasit QariVice President-Information & Digital TechnologyKey CompetitorsSoleno TherapeuticsNASDAQ:SLNOVivani MedicalNASDAQ:VANIENDRA Life SciencesNASDAQ:NDRAHelius Medical TechnologiesNASDAQ:HSDTTivic Health SystemsNASDAQ:TIVCView All CompetitorsInsiders & InstitutionsInternational Assets Investment Management LLCBought 349,575 shares on 1/30/2023Ownership: 0.491%Daniel S GoldbergerBought 5,000 shares on 12/14/2022Total: $1,750.00 ($0.35/share)Joseph P ErricoBought 100,000 shares on 12/13/2022Total: $33,000.00 ($0.33/share)Daniel S GoldbergerBought 5,000 shares on 12/12/2022Total: $1,600.00 ($0.32/share)Daniel S GoldbergerBought 10,000 shares on 12/8/2022Total: $2,800.00 ($0.28/share)View All Insider TransactionsView All Institutional Transactions ECOR Stock - Frequently Asked Questions Should I buy or sell electroCore stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for electroCore in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ECOR shares. View ECOR analyst ratings or view top-rated stocks. What is electroCore's stock price forecast for 2023? 4 brokers have issued 1 year price targets for electroCore's shares. Their ECOR share price forecasts range from $1.50 to $330.00. On average, they anticipate the company's stock price to reach $165.75 in the next twelve months. This suggests a possible upside of 44,697.3% from the stock's current price. View analysts price targets for ECOR or view top-rated stocks among Wall Street analysts. How have ECOR shares performed in 2023? electroCore's stock was trading at $0.2568 at the beginning of the year. Since then, ECOR stock has increased by 44.1% and is now trading at $0.37. View the best growth stocks for 2023 here. When is electroCore's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023. View our ECOR earnings forecast. How were electroCore's earnings last quarter? electroCore, Inc. (NASDAQ:ECOR) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. The firm earned $1.49 million during the quarter, compared to analysts' expectations of $1.58 million. electroCore had a negative net margin of 283.41% and a negative trailing twelve-month return on equity of 72.36%. During the same quarter last year, the business posted ($0.10) EPS. What guidance has electroCore issued on next quarter's earnings? electroCore updated its fourth quarter 2022 earnings guidance on Tuesday, January, 17th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.50 million-$2.50 million, compared to the consensus revenue estimate of $2.17 million. What other stocks do shareholders of electroCore own? Based on aggregate information from My MarketBeat watchlists, some companies that other electroCore investors own include T2 Biosystems (TTOO), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vaxart (VXRT), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Acasti Pharma (ACST), Onconova Therapeutics (ONTX) and OPKO Health (OPK). When did electroCore IPO? (ECOR) raised $64 million in an IPO on Friday, June 22nd 2018. The company issued 4,300,000 shares at $14.00-$16.00 per share. Evercore ISI and JMP Securities acted as the underwriters for the IPO and BTIG was co-manager. What is electroCore's stock symbol? electroCore trades on the NASDAQ under the ticker symbol "ECOR." Who are electroCore's major shareholders? electroCore's stock is owned by a number of institutional and retail investors. Top institutional shareholders include International Assets Investment Management LLC (0.49%). Insiders that own company stock include Brian M Posner, Daniel S Goldberger, John P Gandolfo, Joseph P Errico, Thomas J Errico, Thomas J Errico and Trevor J Moody. View institutional ownership trends. How do I buy shares of electroCore? Shares of ECOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is electroCore's stock price today? One share of ECOR stock can currently be purchased for approximately $0.37. How much money does electroCore make? electroCore (NASDAQ:ECOR) has a market capitalization of $26.33 million and generates $5.45 million in revenue each year. The company earns $-17,220,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis. How can I contact electroCore? electroCore's mailing address is 150 ALLEN ROAD SUITE 201, BASKING RIDGE NJ, 07920. The official website for the company is www.electrocore.com. The company can be reached via phone at (973) 290-0097 or via email at investors@electrocore.com. This page (NASDAQ:ECOR) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.